Patients:
The current study was a cohort clinical trial. It was conducted between
May 2018 and December 2019 on sixty patients with CLP who were enrolled
in the Outpatient Clinics at Dermatology Department, Faculty of
Medicine, Faculty of Medicine, South Valley University between May 2018
and December 2019. The study received the approval of Scientific and
Ethics Committees at the Faculty of Medicine, South Valley University.
Informed consent was taken from the participants after detailed
clarifications of the nature of this study.
.
Inclusion criteria: Patients with CLP diagnosed clinically.
Exclusion criteria: CLP patients with other autoimmune diseases
like systemic lupus, rheumatoid or mixed connective tissue diseases,
alcoholic diseases, heart diseases or liver diseases, blood cell
disorders such as anemia or leucopenia, bone marrow dysfunction, nursing
or pregnant women, kidney disease, infants or children,
photo-exaggerated patients, previous NB-UVB therapy or systemic therapy
in 6 months prior to the first LP therapy, history of dysplastic nevi,
malignant skin lesions, and drug-treated patients causing
photosensitivity or cutaneous pigmentations within 60 days before the
initiation of NB- UVB therapy.